Competition Is Heating Up in Covid Boosters. Moderna and Pfizer, Take Heed.

Panorama of a city business district with office buildings and skyscrapers and superimposed data, charts and diagrams related to stock market, currency exchange and global finance. Blue line graphs with numbers and exchange rates, candlestick charts and financial figures fill the image with a glowing light. Sunset light.

As new Covid-19 cases fall, the postpandemic vaccine market grows more interesting. On Wednesday, GlaxoSmithKline and Sanofi, two of the world’s largest vaccine makers, said they would submit a Covid vaccine for U.S. and European regulatory approval. In spring of 2020, many expected the pair’s vaccine to be first out the door. But early results disappointed. They’re now aiming their vaccine largely at the booster market, noting that recipients of different primary vaccines saw neutralizing antibody levels rise 18- to 30-fold when boosted with their vaccine.


Is Now the Time to Buy or Sell? 7 Stocks to Consider During Turbulent Times.

Previous article

2 Nasdaq ETFs for Q2 2022

Next article

You may also like


Leave a reply

Your email address will not be published.

More in News